Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations.
Thirty consecutive children scheduled for pediatric cardiac operation with cardiopulmonary bypass were included in the study. Before the operation, the patients were randomly divided into two groups: with aprotinin (n = 15, 30,000 U/kg after induction of anesthesia, 30,000 U/kg added to the prime of the cardiopulmonary bypass or without aprotinin (n = 15). Thrombomodulin, (free) protein S, protein C, and thrombin/antithrombin III complex were measured from arterial blood samples taken after induction of anesthesia (at baseline, before aprotinin) and before, during, and after cardiopulmonary bypass until the first postoperative day. Standard coagulation parameters (antithrombin III, fibrinogen, platelet count, and partial thromboplastin time) were without differences between the groups. Thrombomodulin plasma concentrations were within normal range ( < 40 micrograms/L) and were similar in both groups at baseline. During cardiopulmonary bypass and until 5 hours after cardiopulmonary bypass, however, thrombomodulin plasma levels were significantly lower in the children treated with aprotinin. No further differences were observed on the first postoperative day. Protein C and protein S plasma levels did not differ between the two groups. Thrombin/antithrombin III-complex plasma concentrations increased significantly during cardiopulmonary bypass, however, without showing differences between children with (225 +/- 49 micrograms/L) and without (149 +/- 31 micrograms/L) aprotinin treatment. Blood loss and the need for homologous blood and blood products did not differ significantly between the two groups. We concluded that administration of aprotinin resulted in reduced thrombomodulin plasma levels in pediatric patients undergoing cardiac operation without altering protein C/protein S plasma concentration. The exact role of aprotinin in endothelium-derived coagulation should be further studied.
Boldt
J
J
Department of Anesthesiology, Justus-Liebig-University Giessen, Germany.
Zickmann
B
B
Schindler
E
E
Welters
A
A
Dapper
F
F
Hempelmann
G
G
D000990:Antithrombin III / Q000378:metabolism; D007611:Aprotinin / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002315:Cardiopulmonary Bypass; D002675:Child, Preschool; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D006330:Heart Defects, Congenital / Q000097:blood / Q000601:surgery*; D006801:Humans; D010447:Peptide Hydrolases / Q000378:metabolism; D011486:Protein C / Q000378:metabolism*; D017293:Protein S / Q000378:metabolism; D018180:Thrombomodulin / Q000378:metabolism*
D011486:Protein C; D017293:Protein S; D018180:Thrombomodulin; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D007611:Aprotinin; D010447:Peptide Hydrolases